MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ
1.970
-0.090
-4.37%
Opening 12:48 12/05 EST
OPEN
2.080
PREV CLOSE
2.060
HIGH
2.090
LOW
1.950
VOLUME
1.33M
TURNOVER
--
52 WEEK HIGH
3.390
52 WEEK LOW
0.7900
MARKET CAP
87.51M
P/E (TTM)
-1.8077
1D
5D
1M
3M
1Y
5Y
1D
After-Hours Biotech Rally: Clene Surges Ahead Of ALS Update; Werewolf, Biomea, Dyne Also Climb
NASDAQ · 2d ago
Weekly Report: what happened at OTLK last week (1124-1128)?
Weekly Report · 4d ago
Biotech Stocks Facing FDA Decision In December 2025
NASDAQ · 11/27 15:07
Weekly Report: what happened at OTLK last week (1117-1121)?
Weekly Report · 11/24 09:57
Weekly Report: what happened at OTLK last week (1110-1114)?
Weekly Report · 11/17 09:57
H.C. Wainwright Sticks to Its Hold Rating for Outlook Therapeutics (OTLK)
TipRanks · 11/14 23:39
FDA Accepts Outlook Therapeutics' Resubmitted BLA For ONS-5010 In Wet AMD, Decision Due This Month
NASDAQ · 11/14 08:24
FDA Accepts Outlook Therapeutics' Resubmitted BLA For ONS-5010 In Wet AMD, Decision Due In December
NASDAQ · 11/14 08:24
More
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

Webull offers Outlook Therapeutics Inc stock information, including NASDAQ: OTLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OTLK stock methods without spending real money on the virtual paper trading platform.